Difficulty: Medium
Average Score: 85%
Practice
Levodopa and carbidopa combination is used to treat Parkinsonian disease because carbidopa
Correct answer
D
Rationale
In the treatment of Parkinson's disease, the combination of levodopa and carbidopa is commonly used to manage symptoms effectively. The correct answer, D) Reduces levodopa-induced vomiting and nausea, is the most appropriate choice because carbidopa plays a crucial role in this regard. Carbidopa itself does not cross the blood-brain barrier, so it does not enter the CNS to impact dopamine levels directly like levodopa does. Instead, carbidopa works peripherally to inhibit the enzyme DOPA decarboxylase, which prevents the conversion of levodopa into dopamine before it reaches the brain. This results in more levodopa being available to be converted into dopamine centrally within the brain, leading to improved symptomatic relief in Parkinson's disease without increasing dopamine levels in the periphery, which can cause adverse effects like nausea and vomiting.
Option A) Selectively stimulates dopa decarboxylase is incorrect because carbidopa actually inhibits dopa decarboxylase.
Option B) Enters the CNS and increases dopamine in the nigro-striatum is incorrect because carbidopa does not cross the blood-brain barrier to directly increase dopamine levels in the brain.
Option C) Reduces levodopa-induced dyskinesias is incorrect because carbidopa's main role is in reducing the peripheral side effects of levodopa, not dyskinesias.
Understanding the mechanism of action of carbidopa in combination with levodopa is essential for healthcare professionals to optimize treatment outcomes in patients with Parkinson's disease. By inhibiting the peripheral conversion of levodopa to dopamine, carbidopa helps maximize the therapeutic benefits of levodopa while minimizing adverse effects, ultimately improving the quality of life for individuals with Parkinson's disease.
Option A) Selectively stimulates dopa decarboxylase is incorrect because carbidopa actually inhibits dopa decarboxylase.
Option B) Enters the CNS and increases dopamine in the nigro-striatum is incorrect because carbidopa does not cross the blood-brain barrier to directly increase dopamine levels in the brain.
Option C) Reduces levodopa-induced dyskinesias is incorrect because carbidopa's main role is in reducing the peripheral side effects of levodopa, not dyskinesias.
Understanding the mechanism of action of carbidopa in combination with levodopa is essential for healthcare professionals to optimize treatment outcomes in patients with Parkinson's disease. By inhibiting the peripheral conversion of levodopa to dopamine, carbidopa helps maximize the therapeutic benefits of levodopa while minimizing adverse effects, ultimately improving the quality of life for individuals with Parkinson's disease.